Systems for protein biosynthesis can be broadly classified, according to their mechanism and thc sclective action of drugs on thcir reactions, in two groups: the prokaryotic type (including bacterial, mitochondrial and chloroplasts systems) and the eukaryotic type (including cytoplasmic systems from mammals, higher plants, green algae, yeast, fungi and protozoa).
THE MECHANISM OF PROTEIN SYNTHESIS
Translation of mRNA in protein takes place at the ribosome level. As shown in Figure 1 the ribosome has two subunits which are separated after synthesis of the polypeptide chain is finished. W e can distinguish along the ribosome, and including the subunits, two sites: the donor-or P-site and the acceptor-or A-site. The peptidyl transferase centre, which catalyzes peptide bond formation, is integrated into the structure of the larger ribosome subunit; part of this centre is on the P-site whereas another part is on the A -site. The overall reactions taking place in the biosynthesis of proteins by E. coli ribosomes according to the two entry sites translocation model is shown in Figure 2 1 . For the purpose of understanding the whole process, it can be divided in three phases: (a) initiation, (b) elongation and (c) terrnination ( Figure 2) .
The initiation phase starts with the initiator formyl-methionyl-tRNA coded by the initiator triplet AUG at the 5' end ofthe mRNA and the order of nucleotide triplets in the 3' direction determines the order in which subsequent aminoacyl-tRNA bind to the mRNA-ribosome complex. The anticodon region of tRNA is recognized and its interaction with mRNA (Figures 2a and 2b) . In a further reaction a 50S ribosome subunit joins the mRNA-30S-f-Met-tRNA complex to complete the initiation complex with f-Met-tRNA bound to the donor-or P-site (Figure 2c ). One GTP molecule is cleaved into GDP and Pi in the initiation phase; after the joining ofthe 50S subunit (Figure 2c ). lt is known that besides the codon-anticodon interaction at the Ievel of the 30S ribosomal subunit, some portions of the tRNA, in particular the f-Met-bearing moicty, interact with the 50S subunit. The specificity for the initiating role of f-Met-tRNAr and its binding to the P-site is due to the a-NH 2 group of the methionine being blocked by formylation and to the unique structure of the tRNAF.
In the elongation phase the aminoacyl-tRN A determined by the nucleotide triplet adjacent to the initiation codon is bound to the ribosomal acceptoror A-site (Figure 2d 1 ) . Prior formation of the complex [ elongation factor (EF) Tu-AArtRNA 1 -GTP] is required which in the binding reaction splits and EF Tu· GDP + Pi is separated. Once the f-1\1et-tRNAr is in the P-site and AA rtRNA 1 is bound to the A-site, peptide bond .färmation takes place catalyzed by the peptidyl traniferase which is an integral part of the 50S ribosome subunit (Figure 2e 1 ) . Peptide bond formation takes place by transfer of the f-l\1et mo_iety in such a way that the ·· COOH group of methionine is linked to the cr-NH 2 group of the amino acid AArtRNA 1 bound to the A-site. The stripped tRNAr is then released from the P-site and the f-Met-AArtRNA 1 moved to the P-site in a complex step known as translocation (Figure 2f 1 ). The elongation factor EFG and GTP are required in this reaction and one molecule ofGTP is cleaved to GDP +Pi. Movement of the mRNA in the direction 5' ~ 3' is coupled to movement of the f.:.Met-AA 1 -tRNA 1 from the A-to the P-site. Translocation results in the positioning of the next codon into site A which in turn allows entry and 356 specification of AA 2 -tTNA 2 (Figure 2d 2 ) in a reaction similar to that of AA 1 -tRNA 1 binding as described above. The ribosemal peptidyl transferase centre will then transfer the f-Met-AA 1 -tRNA 1 to the A-site thus forming f-Met-AA 1 -AA 2 -tRNA 2 . By repetition ofthe steps involved in the elongation cycle (aminoacyl-tRNA binding, peptide bond formation, translocation) the growth of the polypeptidyl-tRNA chain takes place with the polypeptide bound to the ribosome through the tRNA carrying the last amino acid incorporated into the chain. For the termination phase a chain-terminating codon (nonsense codon) (either UAA or UAG or UGA) is recognized and the bond between the peptidyl and tRNA moieties of peptidyl-tRNA is cleaved in a reaction reqtiiring the release factors (either R 1 or R 2 ) and the supernatant factor S (Figure 2g) .
Basically the same mechanism for protein synthesis as in E. coli is found in organisms other than bacteria. However there are at least two broad 357 classes of systems for protein synthesis; one of them is the prokaryotic type (including bacteria, blue-green algae, mitochondria, chloroplasts and possibly nuclei) and the other one is the eukaryotic type (including systems from the cytoplasm of yeast, fungi, green algae, protozoa, higher plants and mammalian cells). Since bacterial ribosomes have a sedimentation coefficient of 70 svedbergs, ribosomes of the prokaryotic systems have been known frequently altogether as '70S type ribosomes' although it is now known that mitochondrial ribosomes are certainly smaller. Eukaryotic ribosomes are generally known as '80S type ribosomes' as their sedimentation coefficient is close to that figure. Bacterial ribosome subunits are 50S and 30S whereas those 6f eukaryotic ribosomes are 60S and 40S. The ribosomal subunits in eukaryotic type ribosomes perform similar functions to their prokaryotic counterpärts, namely peptide bond formation on the larger subunit and codon-anticodon recognition in the smaller one (see Figure 1) . However, functional differences between the prokaryotic and eukaryotic types of systems for protein synthesis are shown not only in the ribosomes but also in the initiatorandin the different supernatant factors (initiation, elongation and release factors), since there is ample evidence that ribosomes and supernatant factors can be crossed between widely different systems belonging to the same type but not between systems of different types. The elongation factors EF -1 and EF -2 have been shown to have in eukaryotic systems a role rather similar to the bacterial factors EF-T and EF -G respectively; the release factor R has been shown to be required in eukaryotic systems and initiation factors have been isolated from eukaryotic cells but are not so weil resolved yet as in bacterial systems. Furthermore some important differences have been shown within the prokaryotic type ribosomes since the 5S ribosomal RNA is known tobe present in bacterial and chloroplast ribosomes but has never been found in mitochondrial ribosomes. Perhaps due to this difference no reconstitution of active ribosomes has been observed when the small subunit of mitochondrial ribosomes and the large subunit from bacterial ribosomes or vice-versa are mixed whereas there is reconstitution of active ribosomes when hybrid mixtures of chloroplasts and bacterial ribosome subunits are mixed. However for the purpose of the antibiotic action, we can consider, broadly speaking, all prokaryotic systems as a unit.
SELECTIVITY OF PROTEIN SYNTHESIS INHIBITORS
Most of the antibiotics known to block protein synthesis act at the ribosome Ievel. Since there are at least two types of systems for protein synthesis, their inhibitors can be classified according to their specificity, into those affecting systems of (a) the prokaryotic type, (b) the eukaryotic type and (c) both the prokaryotic and the eukaryotic types (Table 1) 2 -10 . Some of these inhibitors bind or affect directly either of the elongation factors ( e.g. diphtheria toxin, fusidic acid and emetine) but most ofthem interact directly with the ribosome. There are still discrepancies regarding some of the results presented in Table 1 . An important one concerns diphtheria toxin which is indicated in this EF -2 of eukaryotic, systems as accepted by most workers 11 -14 : however, one group maintains that diphtheria toxin also binds specifically to the small subunit of bacterial ribosomes blocking the subsequent binding of 359 aminoacyl-tRNA 15 -17 . Also in a few cases it appears that antibiotic sensitivity of systems of a given type differs within the different specific systems. For instance although EF -G from Neurospora crassa has been found tobe interchangeable with bacterial EF -G 18 , this factor from bacteria is sensitive to fusidic acid whereas the EF -G from N eurospora is not affected by this antibiotic 19 . Another interesting example is that of the antibiotics erythromycin, lincomycin, neomycin, kanamycin and streptomycin which have been shown to block protein synthesis by bacterial and yeast ribosomes but have been reported not to be active on ribosomes from mammalian mitochondria20· 21 . Two of the tylophora alkaloids (cryptopleurinc and tylophorine) although included in Tahle 1 as specific inhibitors of eukaryotic systems have also been reported to have a certain effect on yeast mitochondrial ribosomes 22 . Finally , not yet well-resolved cell-free systems from some mammalian structures have been reported to be sensitive to chloramphenicol and resistant to cycloheximide 23 contrarily to what might be predicted from the selectivity indicated in Tahle I. However most of these apparently anomalaus or exceptional results have only been reported by single groups of workers 15 -23 .
RffiOSOME SUBUNITS AS SPECIFIC TARGETS OF ANTffiiOTIC ACTION
The available methods to determine on which ribosome subunit a given antibiotic acts can be summarized as follows; (a) binding of radioactive antibiotics or competition with this binding; (b) reconstitution of hybrid ribosomes from ribosome subunits derived from antibiotic-sensitive and resistant cells, followed by studies on sensitivity of these reconstituted ribosomes to the required antibiotic; (c) studies on protein-synthesizing activity of ribosomes reconstituted from ribosome subunits pretreated independently with the required antibiotic followed by subsequent removal of the unbound inhibitor (by gel filtration, centrifugation, filtration or any other possible method) before the reconstitution experiments; (d) effects of antibiotics on a function specifically associated with a ribosome subunit which can be studicd in the absence of the other subunit; and (e) it can be assumed that a number of antibiotics known to act on both bacterial and eukaryotic protein synthesis do so by blocking homologaus steps in one or another case. Concerning point (d) indicated above we know at least three functions which can be carried out by the small ribosome subunit in the absence of the large subunit: (a) binding of mRNA, (b) formation of the complex aminoacyl-tRNA-small subunit-mRNA and (c) formation of the complex f-Met-tRNA-30S-AUG or natural mRNA. There are also a number of functions specifically catalyzed by the larger ribosome subunit:
(a) peptide bond formation, (b) EF -T -dependent (in prokaryotic systems) and EF-1-dependent (in eukaryotic systems) GTP hydrolysis which normally takes place coupled to aminoacyl-tRNA binding to the ribosome and (c) EF -G-dependent (in prokaryotic systems) and EF -2-dependent (in eukaryotic systems) which normally takes place coupled to the complex step of translocation. By using a number of the experimental approaches indicated above it has been possible to elucidate the ribosome subunit in which some antibiotics act ( Tabfes 2 and 3). Although fusidic acid is known to affect directly EF -G (in prokaryotic systems) and EF -2 (in eukaryotic systems) it is included in Tabfes 2 and 3 as acting on the !arger ribosome subunit since the antibiotic has been shown to bind forming thecomplex EF -G-or EF -2-larger ribosome subunit-GDP-fusidic acid 24 • 25 .
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INHffiiTORS OF mE INITIATION PHASE
Most of the inhibitors which are known to block the initiation phase of protein synthesis are shown in Table 4 . Most of these compounds interact 361
with the smaller ribosome subunit. The antibiotic edeine A 1 and the compounds aurintricarboxylic acid, poly(dextran sulphate) and poly(vinyl sulphate) by binding to the smaller ribosome subunit of either prokaryotic or eukaryotic ribosomes block codon-anticodon interaction of the initiator f-Met-tRNAF and the initiation of protein synthesis is inhibited. Consequently the above inhibitors also block codon-anticodon interaction of peptidyl-tRNA ofthe growing chains at the Ievel ofthe small subunit which is supposed to take place at the same place as the codon-anticodon interaction of the initiator; because of this, aurintricarboxylic acid, edeine A 1 , poly-(dextran sulphate) and poly(vinyl sulphate) arealso inhibitors of the elongation phase. Furthermore these inhibitors have been shown to block equally well binding of f-Met-tRNA and aminoacyl-tRNA to the small subunit. This might be considered a surprising result since the two-sites translocation model admits binding of donor and acceptor substrates taking place to different sites of the subunit (Figures 1 and 2) ; consequently data with the above inhibitors are presented by some workers as supporting a different variant of the translocation model with a single site of codonanticodon interaction on the smaller subunit.
The antibiotics streptomycin, dihydrostreptomycin, kanamycin, gentamycin and paromomycin interact with the 30S subunit of prokaryotic ribosomes and do not appear to affect any of the steps 2a and 2b but destabilize the entire initiation complex formed in step 2c when the 50S subunit joins the f-Met-tRNA-mRNA-30S complex. This is probably a consequence of some distortion in the P-site since these antibiotics are also inhibitors of the elongation cycle by causing polysome breakdown. Antibiotics blocking binding of the 3' end of f-Met-tRNA to the P-site of the peptidyl-transferase centre ofthelarger subunit (see Table 7 ) The main effect of the antibiotic pactamycin is located in the smaller subunit of either 70S or 80S ribosomes. By interacting with the small subunit pactamycin blocks formation of the complex f-Met-tRNA-30S-mRNA in bacterial systems and probably the equivalent reaction taking place in 80S type ribosomes.
A number of antibiotics have been shown toblock peptide bond formation by interacting with the peptidyl transferasc centre of the larger ribosome subunit. Some of these antibiotics have been shown in ccll-free systems to block interaction ofthe CCA-Met-f-or CACCA-Leu-Ac-with the donor-site of the peptidyl transferase centre ( Table 7) . These inhibitors might be expected to block correct initiation of protein synthesis; in fact this mode of action has already been reported for some of these antibiotics.
INHffiiTORS OF THE ELONGATION CYCLE Inhibitors of aminoacyl-tRNA binding
The best known inhibitors of aminoacyl-tRNA binding to the ribosome are shown in Table 5 . Included in this Table are edeine A 1 , aurintricarboxylic acid, poly(dextran sulphate) and poly(vinyl sulphate) which, as indicated above, block interaction codon-anticodon to both A-and P-sites of the smaller subunit. On the other band the tetracycline group of antibiotics specifically block codon-anticodon interaction at the A -site of the smaller subunit.
A number of antibiotics included in the siomycin group have been shown toblock aminoacyl-tRNA binding to bacterial ribosomes at the level of the 50S subunit. Fusidic acid forms the complex fusidic acid-EF -G (or EF -2)-ribosome-GDP which prevents under certain conditions translocation (see Table 8 ) but also aminoacyl-tRNA binding tothelarger ribosomal subunit of either bacterial or eukaryotic ribosomes. It is interesting to quote that fusidic acid has been reported to have no effect on N eurospora mitochondrial systems 19 . Some of the inhibitors of peptide bond formation have been shown to block binding of the terminal CCA-aminoacyl to the acccptor-site of the peptidyl transferase centre ( Table 7) and might be considered not only as inhibitors of peptide bond formation but also as inhibitors of aminoacyltRNA binding at the level ofthelarger ribosomal subunits.
Inhibitors of peptide lfond .formation
The antibiotic puromycin is a structural analogue of the 3' -aminosyladenosine moiety of aminoacyl-tRNA; therefore puromycin acts on the A-site of the peptidyl transferase centre of prokaryotic and eukaryotic ribosomes forming a peptide bond with the initiator amino acid and blocking the correct peptide bond formation. Antibiotics of the chloramphenicol, streptogramin A, lincomycin and some macrolide antibiotics having the mycaminose-mycarose moiety have been shown toblock peptide bond formation in most of the experimental systems from bacteria which have been devised (Table 6 ) alt~<?u~h rec~nt results in polysomal systems suggest that some of these ant1b10ttcs mtght not be proper inhibitors of peptide bond formation in intact bacteria 10 . Inhibitors of codon-anticodon interaction at the A-and Psite~ of the smaller subunit peptidyl transferase centre (see Table 7) ;;
Analogues of the aminoacyl-tRNA forming a peptide bond with substrates bound to the P~site 
Puromycin
The antibiolies actinobolin, amicetin, blasticidin S, gougerotin and sparsomycin have been found toblock peptide bond formation in prokaryotic and eukaryotic systems. However actinobolin is active in some of the systems and the activity of amicetin is very small in some of the ribosomes of the eukaryotic type tested. The antibiotic anisomycin is a very ~fficient inhibitor of peptide bond formation by ribosomes of the eukaryotic type.
For the reaction ofpeptide bond formation (Figure 2e 1 ) the correct binding ofthe 3' end ofthe substrates to the donor-and acceptor-sites ofthe peptidyl transferase centre is required. Studies on substrate binding have shown that some of the inhibitors of peptide bond formation block binding of the substrate to the acceptor-site ofthe peptidyl transferase centre whereas some others inhibit substrate binding to both donor-and acceptor-sites ( Table 7) .
'läble 7. Inhibitors of substrate binding to the peptidyl transferase centre
Inhibitors of CACCA-Leu-Ac binding to the P-site
Inhibitors of UACCA-Leu binding to the A -site The step of translocation is one of the most complex and controversial in protein synthcsis. Most of the systems used to study translocation are based on the extent of the puromycin reaction before and after treatment with elongation factor-G or -2 which is required for the GTP hydrolysis necessary for translocation. Forthis reason inhibitors of G<lependent GTP hydroly.sis are usually considered as inhibitors of translocation.
Antibiotics of the siomycin group bind to the 50S subunit of bacterial ribosomes and block EF -G dependent GTP hydrolysis and the coupled translocation (Table 8 ). It is not well known where the site of EF -G interaction with the 50S ribosome su bunit is located; however, since antibiotics of the siomycin group have also been shown to block aminoacyl-tRNA 367 D. VAZQUEZ binding to the 50S subunit ( Table 5 ) the results suggest that the binding site for EF -Gis overlapping the A-site of the 50S subunit.
Resistance to fusidic acid in bacteria is due to alterations in elongation factor-G, locating in this factor the action of the antibiotic. However ~t has beeb shown that fusidic acid is active in bacterial as weil as eukaryotlc systems allowing a single round of GTP hydrolysis and forming initially a stable complex fusidic acid-EF -G (or EF -2}-ribosome-GDP which prevents translocation and subsequent hydrolysis of GTP.
Acting on prokaryotic systems
Siomycin group: Siomycin Sporangiomycin Thiopeptin Thiostrepton Other inhibitors of the elongation cycle.
All the inhibitors included in Tables 5-8 obviously block the elongation cycle by preventing some of their partial reactions (aminoacyl-tRNA binding, peptide b9nd formation and translocation). However some other inhibitors of the elongation cycle have to be considered. Besides inhibiting the initiation phase and probably as a consequence of the same interaction with the ribosome the streptomycin group of aminoglycoside antibiotics are known to block in bacterial systems polypeptide elongation by causing polysome breakdown (Table 9 ).
There is evidence that a number of antibiotics are inhibitors of the elongation cycle but there is no clear indication of the specific reaction inhibited by some of them. By exclusion of other steps of protein synthesis most of these compounds are usually considered as inhibitors of translocation but certainly there is no clear positive indication in favotir of this hypothesis. Among these inhibitors we can include a number of macrolides and antibiotics of the streptogramin B group ( Table 9) . Peptide chain termination is a complex reaction requiring (a) recognition of the nonsense terminating codon, (b) peptidyl-tRNA hydrolysis which is catalyzed by the peptidyl transferase centre and (c) the release reaction specifically catalyzed by the release factors R 1 , R 2 and S in bacteria and by the release factor R in mammalian systems. We do not know of any specific inhibitor of this step (c). Recognition of the termination codon UAG has been shown in bacterial systems to be inhibited by Streptomycin and tetracycline (Table 1 0); as tetracycline also binds to SOS type ribosomes it is likely that this antibiotic also inhibits termination in eukaryotic systems. Peptidyl-tRNA hydrolysis required for peptide chain termination is known to involve the peptidyl esterase centre ofthelarger ribosome subunit in a reaction very similar in requirements and optimal conditions to that of peptide bond formation. It has been shown indeed that all peptide bond formation inhibitors tested (Table 6 ) are also inhibitors of the peptidyltRNA hydrolysis required for the termination reaction (Table 1 0) ~ the specificities of the inhibition are similar as in the case of inhibition of peptide bond formation (Table 6) . 369
